We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo COVID-19 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology BioResearch Industry

Blood Test 24 Hours After Start of Chemotherapy Predicts Survival

By LabMedica International staff writers
Posted on 11 Jan 2023

Acute myeloid leukemia is an aggressive blood cancer with poor survival. Despite high rates of initial chemotherapy response, patients often relapse due to the selection and development of chemotherapy-resistant leukemic cells. The response to therapy is currently measured after weeks to months of treatment, thereby losing important time. Now, researchers have found a new method that within hours can predict if certain cancer patients will survive or not after chemotherapy.

Researchers at the University of Bergen (Bergen, Norway) have discovered that an immediate response to chemotherapy can be measured by investigating the functional properties of the leukemic cells. In their study, the researchers employed mass cytometry to investigate intracellular signaling networks in peripheral blood samples from 32 newly-diagnosed acute myeloid leukemia patients during the first 24 hours of standardized induction chemotherapy. By correlating initial intracellular signaling response to five-year overall survival, the researchers demonstrated that early response evaluation by mass cytometry at 24 hours can identify patients with suboptimal treatment response to standard induction therapy.


Image: A new method can quickly predict if certain cancer patients will survive or not after chemotherapy (Photo courtesy of Pexels)
Image: A new method can quickly predict if certain cancer patients will survive or not after chemotherapy (Photo courtesy of Pexels)

"When treating patients with leukemia, it is challenging to quickly follow if the patient is responding to therapy or not," said Benedicte Sjo Tislevoll, researcher at the University of Bergen and leader of the new study. "Our results show that the protein ERK1/2 increases within the first 24 hours of chemotherapy in patients who have a poor response to therapy. We believe that this protein is responsible for the cancer cells' resistance to chemotherapy and can be used to distinguish responders from non-responders."

"We think that this is an important key in our understanding of cancer, and our aim is to use this information to change treatment early for patients who are not responding to therapy," Tislevoll concluded.

Related Links:
University of Bergen 


New
Platinum Supplier
Laboratory Quality Control
Acusera
New
Total Immunoglobulin E (IgE) Test
ALLERgen Total-IgE ELISA Kit
New
Clinical Centrifuge
BenchMate C6V
New
RSV & FLU A/B One-Step Immunochromatographic Test
SIMPLE RSV-FLU A+B

Latest Hematology News



SEROSEP